Document Detail

The anticonvulsant effects of the enantiomers of losigamone.
MedLine Citation:
PMID:  10578135     Owner:  NLM     Status:  MEDLINE    
1 Losigamone is a novel anticonvulsant undergoing phase III clinical trials in patients with partial and secondary generalized seizures. This study investigated the effects of the S(+)- and R(-)- enantiomers of losigamone on endogenous amino acid release from BALB/c mouse cortical slices, spontaneous depolarizations in the cortical wedge preparation of the DBA/2 mouse and audiogenic seizures in DBA/2 mice. 2 S(+)-losigamone (100 and 200 microM) significantly reduced both potassium- and veratridine-elicited release of glutamate and aspartate from cortical slices. R(-)-losigamone had no effect on release at concentrations up to 400 microM. 3 Cortical wedges exhibit spontaneous depolarizations when perfused with magnesium-free artificial cerebrospinal fluid. S(+)-losigamone significantly reduced these depolarizations at 50-200 microM whilst R(-)-losigamone had a significant effect at 200-800 microM. 4 DBA/2 mice are susceptible to audiogenic seizures and S(+)-losigamone dose-dependently (5, 10 and 20 mg kg-1, i.p.) significantly inhibited clonic/tonic convulsions with 91% of the mice protected at 20 mg kg-1. There was no protection at 20 mg kg-1 with R(-)-losigamone. 5 These results, from both in vitro and in vivo experiments, confirm that the pharmacological activity profiles of the two losigamone enantiomers are not identical and suggest further that excitatory amino acid-mediated processes are involved in the mode of action of S(+)-losigamone whereas R(-)-losigamone does not possess such properties. For the treatment of neurological conditions involving exaggerated excitatory amino acid function the use of S(+)-losigamone might therefore be more effective clinically than losigamone or its R(-)-enantiomer.
F A Jones; J A Davies
Related Documents :
8487075 - Cardiovascular responses to global cerebral ischemia: role of excitatory amino acids in...
10506525 - Changes in amino acid concentrations over time and space around an impact injury and th...
3509955 - Ibotenic acid analogues. synthesis and biological testing of two bicyclic 3-isoxazolol ...
2866465 - Ketamine acts as a non-competitive n-methyl-d-aspartate antagonist on frog spinal cord ...
20971205 - Genetic engineering of fatty acid chain length in phaeodactylum tricornutum.
17139105 - Antiproliferative constituents from umbelliferae plants. ix. new triterpenoid glycoside...
Publication Detail:
Type:  Comparative Study; In Vitro; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of pharmacology     Volume:  128     ISSN:  0007-1188     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  1999 Nov 
Date Detail:
Created Date:  2000-01-24     Completed Date:  2000-01-24     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1223-8     Citation Subset:  IM    
Department of Pharmacology, Therapeutics and Toxicology, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amino Acids / drug effects,  secretion
Anticonvulsants / pharmacology*
Cerebral Cortex / drug effects,  physiology,  secretion
Dose-Response Relationship, Drug
Furans / chemistry,  pharmacology*
Mice, Inbred BALB C
Mice, Inbred DBA
Potassium / pharmacology
Seizures / prevention & control
Veratridine / pharmacology
Reg. No./Substance:
0/Amino Acids; 0/Anticonvulsants; 0/Furans; 71-62-5/Veratridine; 7440-09-7/Potassium; 84R8O3QM2G/losigame

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Non-adrenergic binding of [3H]atipamezole in rat kidney--regional distribution and comparison to alp...
Next Document:  Endothelin alters the reactivity of vasa vasorum: mechanisms and implications for conduit vessel phy...